Compare BioNano Genomics Inc (BNGO) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Western Alliance Bancorporation — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Western Alliance Bancorporation trades at $80.41 (market cap $8.77B). The key difference: Western Alliance Bancorporation is far larger — about 664.4× BioNano Genomics Inc's market cap, and Western Alliance Bancorporation pays a 2.09% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | WAL | |
|---|---|---|
Market Cap | $13.20M | $8.77B |
Sector | Health | Financials |
52-Week High | $4.92 | $96.08 |
52-Week Low | $1.09 | $66.70 |
Enterprise Value | $15.81M | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Western Alliance Bancorporation (WAL) trades at $80.49, down 0.25% on the day, with a bearish technical signal and mixed fundamentals. The stock shows strong analyst support with a consensus price target of $90.67 and 79% buy ratings, but recent earnings beats are overshadowed by negative operating cash flow and high interest expenses. Recent news highlights strategic lending growth and industry recognition, including a #1 bank ranking in Arizona by Forbes in June 2026.
The outlook is cautiously optimistic given Wall Street's bullish stance and valuation discounts, but risks include cash flow pressures and macroeconomic sensitivity. Upside hinges on execution of lending growth and margin improvement, while downside could stem from credit quality deterioration or rising rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
